Series A13 July 2023

Tenpoint Therapeutics raises $70m in Series A funding to advance regenerative medicine platform.

The Series A round included backing from British Patient Capital, F-Prime Capital, and Sofinnova Partners.

$70.0MSeries A

≈ £53.3M at $1 = £0.7617 on 13 Jul 2023

Tenpoint Therapeutics is a biotechnology company developing cell-based therapeutics and in vivo reprogramming to reverse vision loss. The startup builds on scientific research in ocular therapies to replace lost and dysfunctional tissue in the eye.

Tenpoint Therapeutics has raised $70m in Series A funding to advance its regenerative medicine platform for degenerative ocular diseases. The round drew participation from a group of investors including British Patient Capital, F-Prime Capital, Sofinnova Partners, Qiming Venture Partners USA, Eight Roads, and the UCL Technology Fund.

The Cambridge-based company will direct the capital towards developing its platform to replace multiple cell types lost through inherited and age-related conditions. The startup focuses exclusively on the eye by harnessing advances in regenerative biology.

British Patient Capital contributed £10m to the round through its Future Fund: Breakthrough programme. The investment marks its ninth commitment to the life sciences sector.

From the founder

"At Tenpoint, we are focused exclusively on the eye and on harnessing recent advances in regenerative biology to advance our therapies as we work to change the future for people with vision loss by addressing its underlying causes."

Eddy Anglade

CEO at Tenpoint Therapeutics

Investor perspective

"Tenpoint Therapeutics has been built on the pioneering work of its scientific founders who are recognised leaders in ocular therapies. Their vision combined with research excellence provides the best foundation to develop treatments that could be gamechangers for millions of patients worldwide. Through Future Fund: Breakthrough, we are delighted to support this truly innovative British business with the funding to take the business to the next level."

Catherine Lewis La Torre

CEO, British Patient Capital